🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the battle against drug-resistant strains of the infection, according to researchers.

An International Challenge

Cases of gonorrhoea are on the rise worldwide, with data suggesting in excess of 82 million new cases each year. Especially elevated rates are seen in Africa and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely advancement in the face of growing infection rates, the spread of superbugs and the very limited treatment choices presently on offer.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has classified it as a "high-priority threat". Ongoing monitoring revealed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Therapies Secure Authorization

One new antibiotic, alternatively called a brand name, was cleared by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Scientists believe that targeted use of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in close succession. This drug, which is employed against urinary tract infections, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a unique collaborative effort for drug creation. The charitable organization GARDP partnered with the drug firm Innoviva to see it through.

“This approval represents a huge turning point in the treatment of multidrug-resistant gonorrhoea, which up to this point has been staying ahead of our drug pipeline.”

Testing Results and Global Access

As per results released by a major medical journal, zoliflodacin eradicated more than 90% of cases of the STI. This places it at an comparable level with the current standard treatment, which combines an injection and a pill. The trial involved hundreds of participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, GARDP has the ability to make available and distribute the drug in many developing nations.

Medical professionals on the front lines have shared positive views. Having a single-dose, oral treatment of this kind is seen as a "revolutionary step" for public health efforts. This is viewed as crucial to reduce the burden of the disease for patients and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.